Goldman Sachs has initiated coverage on Elevance Health Inc (ELV) with a Neutral rating, marking the firm's first assessment of the health insurer. This decision reflects Goldman Sachs' analysis of Elevance's business and industry dynamics, as well as its growth prospects.
Elevance Health, headquartered in Indianapolis, operates as a health company, focusing on improving lives and making healthcare simpler. With a market capitalization of $69.9 billion, the company employs over 103,000 full-time workers and operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment provides a comprehensive suite of health plans and services across various member categories, including Medicare and Medicaid.
As of October 13, 2025, Elevance's stock trades at $315.62. The company's financial metrics include a P/E ratio of 12.63 and an EPS of 24.45. Upcoming earnings are set for July 14, 2026, with an estimated EPS of $9.18 and revenue of $53.1 billion. Recent earnings performance has shown mixed results, with a notable Q3 2025 EPS of $6.03, surpassing estimates by 21%.
Analyst ratings provide insights based on financial models and research. While these assessments can be informative, they are based on assumptions that may not always materialize. Investors should consider a range of factors, including company fundamentals and market trends, when making decisions. Analyst ratings can evolve as new information becomes available, highlighting the importance of keeping abreast of market developments.